# Retatrutide: Research Overview — Peptides Long Island > A literature summary of retatrutide (LY3437943), an investigational GIP/GLP-1/glucagon triple receptor agonist in Phase 3 trials. Covers mechanism, Phase 2 trial results, community-reported effects, and safety cautions. A triple GIP/GLP-1/glucagon agonist that posted the biggest weight-loss figures of any incretin-class compound studied so far — and remains investigational, with Phase 3 results not yet published. ## The short version Retatrutide — also called LY3437943 — is a single peptide engineered to activate three separate hormone receptors at once: GLP-1, GIP, and glucagon. Adding that third arm, glucagon, is the key idea: where GLP-1 and GIP mainly reduce appetite, glucagon signaling is proposed to also raise the amount of energy the body burns, working both sides of the weight-loss equation at once. In a 48-week Phase 2 trial, the highest dose tested produced an average -24.2% body-weight change versus -2.1% with placebo — the largest figure reported for any incretin-class compound to date [9]. But *Phase 2* is the operative word: retatrutide is currently in Phase 3 trials (the TRIUMPH program) and has not been approved by the FDA or any other regulator as of this writing [6][9]. This page describes what has been published; it does not recommend a dose, a source, or a course of action for anyone. ## What it is Retatrutide is a 39-amino-acid synthetic peptide built on a GIP-based backbone, acylated with a C20 fatty diacid side chain that binds serum albumin and extends its circulating half-life to support once-weekly dosing. Cryo-electron microscopy work has resolved exactly how it engages all three of its target receptors — GLP-1R, GIPR, and the glucagon receptor (GCGR) — at atomic-scale resolution [7]. That structural work also revealed something counterintuitive: retatrutide is roughly 8.9-fold *more* potent than the body's own GIP at the GIP receptor, but only 0.3-fold and 0.4-fold as potent as the native hormones at the glucagon and GLP-1 receptors, respectively. Put differently, it is not a uniform key for three locks — it engages each receptor differently, a design choice reflected in the distinct shape its binding loop adopts at each one [7]. ## How it works Retatrutide inherits the appetite-suppressing, insulin-boosting pharmacology of GLP-1 and GIP receptor agonism and adds a third mechanism on top: controlled activation of the glucagon receptor. Glucagon normally tells the liver to release stored sugar — the opposite of what an appetite-suppressing metabolic drug wants — but in combination with the insulin-boosting effect of the other two receptor arms, mild glucagon signaling instead appears to raise energy expenditure through fat-burning and heat-generating (thermogenic) processes in the body, with little net effect on blood sugar [6]. The practical result, per a 2025 review of the compound's pharmacology and trial data, is a drug working on both halves of the weight equation simultaneously: eating less (via the GLP-1/GIP arms) and burning more (via the glucagon arm) — a combination the review calls a step-change compared with earlier, dual-receptor incretin compounds [6]. ## What the research shows *Structural basis for triple agonism (2024).* Cryo-EM structures resolved retatrutide's binding to all three of its target receptor complexes at 2.68, 3.26, and 2.84 Å resolution, confirming genuine triple-receptor engagement and detailing the differing potency and binding-loop conformation at each site [7]. *Metabolic liver disease substudy (2024).* In 98 adults with obesity or overweight and metabolic dysfunction-associated liver disease, confirmed by MRI liver-fat measurement and without type 2 diabetes, 12 mg of retatrutide reduced relative liver fat by -82.4% at 24 weeks, with 86% of participants reaching a normal liver-fat level (under 5%); the effect held to 48 weeks [8]. *Phase 2 obesity trial (2023).* In 338 adults with obesity, once-weekly retatrutide at 12 mg produced a mean -24.2% body-weight change versus -2.1% with placebo over 48 weeks. Gastrointestinal side effects were dose-related and mostly mild to moderate, and a dose-dependent rise in heart rate was observed, peaking around week 24 [9]. *Phase 2 type 2 diabetes trial (2023).* In 281 adults with type 2 diabetes over 36 weeks, 12 mg lowered HbA1c by -2.02% at 24 weeks (versus -0.01% with placebo) and reduced body weight by 16.94% by week 36. Mild-to-moderate GI side effects occurred in 35% of participants; there were no cases of severe hypoglycemia and no deaths [10]. *Narrative review (2025).* A synthesis of the full Phase 1/2 program frames the roughly 24% weight-loss figure as a genuine step-change versus prior incretin agents, reviews the glucagon-driven energy-expenditure hypothesis, and notes that the Phase 3 TRIUMPH program is ongoing [6]. ## Reported effects, cautions & safety People describing their experience with retatrutide in research-use online communities report a pattern broadly consistent with the trial data, plus a few effects attributed to its added glucagon arm. **These reports are anecdotal, not clinical evidence** — unverified self-reports with no confirmed doses and no clinical oversight, offered here only because the underlying corpus documents them, and never as a basis for any recommendation. On the benefit side, community members most often describe a near-total quieting of intrusive food thoughts — sometimes called 'food noise going quiet' — alongside rapid, pronounced weight reduction broadly in line with the Phase 2 trajectory, and, in a subset, a mild warmth or thermogenic sensation some attribute to the glucagon receptor arm. On the adverse side, nausea in the hours after injection is the most frequently mentioned complaint, alongside an awareness of a faster resting heart rate that maps to the dose-dependent increase documented in trials, plus sulfur-smelling burps, early fatigue, and constipation. Cited cautions drawn from the clinical and regulatory literature: - **Unverified sourcing.** Because retatrutide is investigational, material obtained outside a registered clinical trial has no confirmed identity, purity, or sterility [6][9]. - **Gastrointestinal adverse events** are dose-related and the leading cause of trial discontinuation at the highest dose [9]. - **Dose-dependent heart-rate increase**, peaking around week 24 in Phase 2 data, with long-term cardiovascular implications not yet characterized by an outcomes trial [9]. - **Hypoglycemia risk rises when combined with insulin or sulfonylurea medications**, an interaction studied in the Phase 2 diabetes trial population [10]. - **Some proportion of weight lost is lean mass rather than fat**, a pattern documented across this compound's broader trial program and one that argues for attention to protein intake and resistance training during rapid weight loss [9][10]. - **Long-term safety is unknown.** Outcomes trials are still running, and no Phase 3 results have been published [6]. ## Where it fits in Metabolic & Weight Research Retatrutide sits in the middle of this guide's evidentiary spectrum: further along than [MOTS-c](/mots-c), which has no completed human trials at all, but a step behind [semaglutide](/semaglutide), which carries FDA approval and a much larger and longer clinical record. Its Phase 2 numbers are the most striking on this site — but a Phase 2 signal is not a Phase 3 confirmation, and this guide treats the two as distinct categories of evidence rather than interchangeable ones. See the [comparison page](/compare) for the full picture. ![Retatrutide research illustration — abstract triple-receptor pathway motifs in cobalt](/images/retatrutide.webp) --- Peptides Long Island pairs every research finding with its citation and its caveat — a field guide to metabolic peptides, not a clinic or a store.